Log in

NASDAQ:TCRRTcr2 Therapeutics Stock Price, Forecast & News

$14.48
-0.89 (-5.79 %)
(As of 07/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.37
Now: $14.48
$15.66
50-Day Range
$10.10
MA: $14.27
$16.85
52-Week Range
$5.84
Now: $14.48
$21.06
Volume158,340 shs
Average Volume106,098 shs
Market Capitalization$348.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCRR
CUSIPN/A
CIKN/A
Phone617-949-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.68 per share

Profitability

Net Income$-47,600,000.00

Miscellaneous

Employees47
Market Cap$348.62 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable

Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.

Tcr2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

How has Tcr2 Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Tcr2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TCRR stock has increased by 68.8% and is now trading at $14.48. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Tcr2 Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tcr2 Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Tcr2 Therapeutics.

When is Tcr2 Therapeutics' next earnings date?

Tcr2 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Tcr2 Therapeutics.

How were Tcr2 Therapeutics' earnings last quarter?

Tcr2 Therapeutics Inc (NASDAQ:TCRR) announced its earnings results on Thursday, May, 14th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.05. View Tcr2 Therapeutics' earnings history.

What price target have analysts set for TCRR?

3 brokerages have issued 1-year price targets for Tcr2 Therapeutics' stock. Their forecasts range from $19.00 to $19.00. On average, they expect Tcr2 Therapeutics' stock price to reach $19.00 in the next year. This suggests a possible upside of 31.2% from the stock's current price. View analysts' price targets for Tcr2 Therapeutics.

Has Tcr2 Therapeutics been receiving favorable news coverage?

Media coverage about TCRR stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Tcr2 Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Tcr2 Therapeutics.

Are investors shorting Tcr2 Therapeutics?

Tcr2 Therapeutics saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 725,700 shares, an increase of 39.7% from the June 15th total of 519,400 shares. Based on an average daily trading volume, of 113,300 shares, the days-to-cover ratio is presently 6.4 days. Currently, 6.0% of the shares of the stock are short sold. View Tcr2 Therapeutics' Current Options Chain.

Who are some of Tcr2 Therapeutics' key competitors?

What other stocks do shareholders of Tcr2 Therapeutics own?

Who are Tcr2 Therapeutics' key executives?

Tcr2 Therapeutics' management team includes the following people:
  • Dr. Garry E. Menzel, Pres, CEO & Director (Age 55)
  • Mr. Robert Hofmeister, Chief Scientific Officer (Age 52)
  • Dr. Alfonso Quintas Cardama M.D., Chief Medical Officer (Age 48)
  • Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 46)

When did Tcr2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is Tcr2 Therapeutics' stock symbol?

Tcr2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

How do I buy shares of Tcr2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tcr2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $14.48.

How big of a company is Tcr2 Therapeutics?

Tcr2 Therapeutics has a market capitalization of $348.62 million. The company earns $-47,600,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. Tcr2 Therapeutics employs 47 workers across the globe.

What is Tcr2 Therapeutics' official website?

The official website for Tcr2 Therapeutics is www.tcr2.com.

How can I contact Tcr2 Therapeutics?

Tcr2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.